Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines

[1]  D. Lu,et al.  Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo , 2004, BMC pharmacology.

[2]  J. Chi,et al.  Effect of Anti-Cancer Drugs on the Binding of 125I-Fibrinogen to Two Leukaemia Cell Lines In Vitro , 2004, The Journal of international medical research.

[3]  M. Cavazzana‐Calvo,et al.  The future of gene therapy , 2004, Nature.

[4]  K. Hellmann.  Dynamics of tumour angiogenesis: Effect of razoxane-induced growth rate slowdown , 2004, Clinical & Experimental Metastasis.

[5]  M. Inaba,et al.  Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine) , 1991, Cancer Chemotherapy and Pharmacology.

[6]  W. Jing,et al.  Inhibition of probimane on lipid peroxidation of rabbit and human erythrocytes , 2003 .

[7]  J. Marx.  A Boost for Tumor Starvation , 2003, Science.

[8]  E. Freireich,et al.  Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. , 2003, Leukemia research.

[9]  M. Sehested,et al.  Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha. , 2003, Molecular pharmacology.

[10]  丁健,et al.  Inhibition of Probimane on Lipid Peroxidation of Rabbit and Human Erythrocytes , 2003 .

[11]  E. Winer,et al.  2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Taraboletti,et al.  Antiangiogenic and antivascular therapy for cancer. , 2001, Current opinion in pharmacology.

[13]  C. Taylor,et al.  Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562 , 2001, British Journal of Cancer.

[14]  L. Da.  Comparison between probimane and razoxane on inhibiting calmodulin activity of rabbit erythrocyte membrane , 2001 .

[15]  M. Okada,et al.  Long-Term Administration of Oral Low-Dose Topoisomerase II Inhibitors, MST-16 and VP-16, for Refractory or Relapsed Non-Hodgkin’s Lymphoma , 2001, Acta Haematologica.

[16]  A. Harris,et al.  A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  B. Hill,et al.  Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action , 2000, Anti-cancer drugs.

[18]  T. Andoh,et al.  Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events , 1994, The Journal of cell biology.

[19]  Lu Da.  Serum Contents of Sialic Acids in Mice Bearing Different Tumors , 1994 .

[20]  D. Lu,et al.  [Distribution of 14C labeled at dioxopiperazine or methyl morpholine group of probimane by whole body autoradiography]. , 1993, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[21]  W. Rhomberg,et al.  Radiotherapeutic enhancement by razoxane. , 1991, Cancer treatment reviews.

[22]  Wu Ying-de.  SHORT TERM RESULTS OF MALIGNANT LYMPHOMA TREATED WITH PROBIMANE , 1990 .

[23]  M. Wang,et al.  [Effects of bimolane and probimane on the incorporation of (3H)TdR, (3H)UR and (3H)Leu into Ehrlich ascites carcinoma cells iv vitro]. , 1988, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[24]  M. Wang,et al.  [Cytokinetic effects of 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5- dioxopiperazin-1-yl) ethane (MST-16) on leukemia L1210 cells in mice]. , 1988, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[25]  M. Wang,et al.  [Antineoplastic action and toxicity of probimane and its effect on immunologic functions in mice]. , 1987, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[26]  D. Witiak,et al.  Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. , 1982, Advances in pharmacology and chemotherapy.